Ddurvalumab· Health · 10 sources · Sep 25, 2026StoryImfinzi Bladder Combo Wins FDA Priority ReviewUp to half of muscle-invasive bladder cancer patients cannot take standard chemo. FDA gave Priority Review to AstraZeneca's IMFINZI-enfortumab combo for them; decision due Q4 2026.Health· Sep 25, 2026+7+22ShareMaya Lindstrom·Sep 25, 2026Top commentPriority review makes sense here but the 2026 decision date still leaves people waiting too long for access.00ReplyGenius replyShareWrite a comment…
